Committed to sharing our science

Committed to sharing our science

391 results available

Efficacy and Safety of Extended Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Oral Presentation, ESC 2025

Tower-Rader, A et al.

August 31, 2025
Incidence and Impact of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Trials

Oral Presentation, ESC 2025

Rowin, et al.

August 30, 2025
Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis

Moderated Poster, ESC 2025

Masri, A et al.

August 30, 2025
Aficamten vs Metoprolol as Monotherapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Oral Presentation, ESC 2025

Garcia-Pavia, P et al.

August 30, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine

Garcia-Pavia, P et al.

August 30, 2025